PTGS2 and breast cancer: Clinical and research data in the past 20 years reveal that cyclooxygenase (COX)2 is overexpressed in a variety of malignant tumors (6–8) and are linked to apoptosis resistance (9), invasive tumor behavior (10) and the poor prognosis of breast cancer (8,11,12).